Logos Global Management LP Buys Shares of 1,050,000 Stoke Therapeutics, Inc. (NASDAQ:STOK)

Logos Global Management LP purchased a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,050,000 shares of the company’s stock, valued at approximately $14,186,000. Stoke Therapeutics accounts for about 1.1% of Logos Global Management LP’s investment portfolio, making the stock its 23rd biggest position.

Other institutional investors have also recently made changes to their positions in the company. Assenagon Asset Management S.A. bought a new position in shares of Stoke Therapeutics in the second quarter worth $19,835,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Stoke Therapeutics in the first quarter worth $1,224,000. SG Americas Securities LLC increased its holdings in shares of Stoke Therapeutics by 610.3% in the second quarter. SG Americas Securities LLC now owns 68,601 shares of the company’s stock worth $927,000 after purchasing an additional 58,943 shares during the period. Vanguard Group Inc. increased its holdings in shares of Stoke Therapeutics by 4.1% in the first quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company’s stock worth $23,160,000 after purchasing an additional 67,052 shares during the period. Finally, Birchview Capital LP increased its holdings in shares of Stoke Therapeutics by 147.1% in the fourth quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock worth $1,105,000 after purchasing an additional 125,000 shares during the period.

Insider Activity

In other news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $13.75, for a total transaction of $137,500.00. Following the completion of the transaction, the insider now directly owns 2,485 shares of the company’s stock, valued at $34,168.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Barry Ticho sold 10,000 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $13.75, for a total value of $137,500.00. Following the completion of the transaction, the insider now directly owns 2,485 shares of the company’s stock, valued at $34,168.75. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Skorpios Trust sold 1,937,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares of the company’s stock, valued at approximately $125,131,843.05. The disclosure for this sale can be found here. Insiders own 11.30% of the company’s stock.

Analyst Upgrades and Downgrades

STOK has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, September 11th. Wedbush reiterated an “outperform” rating and issued a $17.00 target price on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Stoke Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $21.40.

Stoke Therapeutics Trading Down 3.5 %

Shares of NASDAQ:STOK opened at $13.27 on Tuesday. The company has a market cap of $691.65 million, a price-to-earnings ratio of -5.51 and a beta of 0.96. The company has a 50-day moving average price of $14.48 and a 200-day moving average price of $13.24. Stoke Therapeutics, Inc. has a 12 month low of $3.35 and a 12 month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.11. The firm had revenue of $4.83 million during the quarter, compared to the consensus estimate of $3.33 million. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. As a group, research analysts forecast that Stoke Therapeutics, Inc. will post -2.18 EPS for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.